Non-coding RNA therapeutics in the treatment of heart failure

Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):353-360. doi: 10.1093/ehjcvp/pvae027.

Abstract

Non-coding RNA (ncRNA) therapeutics can target either ncRNAs or conventional messenger RNA, offering both superior pharmacokinetics and selectivity to conventional therapies and addressing new, previously unexplored pathways. Although no ncRNA has yet been approved for the treatment of heart failure, in this review we present five most promising pathways and agents that either are in human clinical trials or offer great promise in the near future.

Keywords: Heart failure; Heart failure with reduced ejection fraction; MicroRNA; Non-coding RNA; Therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Gene Expression Regulation
  • Genetic Therapy / methods
  • Heart Failure* / drug therapy
  • Heart Failure* / genetics
  • Heart Failure* / therapy
  • Humans
  • RNA, Untranslated / genetics
  • Recovery of Function
  • Treatment Outcome

Substances

  • RNA, Untranslated